CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine

British Journal of Clinical Pharmacology

Volumn 41, Issue 6, 1996, Pages 605-608

  Carrillo, Juan A ^a   Benitez, Julio ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

caffeine; CYP1A2 activity; gender; smoking; toxicity

Indexed keywords

ACYLTRANSFERASE; CAFFEINE; DRUG METABOLITE; NON PRESCRIPTION DRUG; XANTHINE OXIDASE;

ADULT; ANALGESIA; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIRIUM; DRUG TRANSFORMATION; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; FOOD COMPOSITION; GASTROINTESTINAL SYMPTOM; GENDER; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERHIDROSIS; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POLYURIA; PRIORITY JOURNAL; RESTLESSNESS; SIDE EFFECT; SMOKING; STIMULATION; TINNITUS; TREMOR; VOMITING; WAKEFULNESS;

EID: 0030004771     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.35418.x     Document Type: Article

References (28)

1. Benowitz NL. Clinical pharmacology of caffeine. Ann Rev Med 1990; 41: 277-288.
2. Tang BK, Kadar D, Qian L, Iriah J, Yip J, Kalow W. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin Pharmacol Ther 1991; 49: 648-657.
3. Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993; 53: 503-514.
4. Carrillo JA, Benitez J. Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. Clin Pharmacol Ther 1994; 55: 293-304.
5. Ellinwood EH, Rockwell WJK. Central nervous system stimulants and anorectic agents. In Meyler's Side Effects of Drugs, ed Dukes MNG, Amsterdam: Elsevier Science 1992: 1-29.
6. Stavric B. Methylxanthines: toxicity to humans. 2. Caffeine. Food Chem Toxic 1988; 26: 645-662.
7. Levy M, Zylber-Katz E. Caffeine metabolism and coffee-attributed sleep disturbances. Clin Pharmacol Ther 1983; 33: 770-775.
8. Lane JD, Steege JF, Rupp SL, Kuhn CM. Menstrual cycle effects on caffeine elimination in the human female. Eur J Clin Pharmacol 1992; 43: 543-546.
9. Hardy BG, Lemieux C, Walker SE, Bartle WR. Interindividual and intraindividual variability in acetylation: Characterization with caffeine. Clin Pharmacol Ther 1988; 44: 152-157.
10. James JE, Bruce MS, Lader MH, Scott NR. Self-report reliability and symptomatology of habitual caffeine consumption. Br J Clin Pharmacol 1989; 27: 507-514.
11. Barone JJ, Roberts H. Human consumption of caffeine. In Caffeine: Perspectives from recent research, ed Dews PB, Berlin: Springer-Verlag, 1984: 59-85.
12. Snel J. Coffee and caffeine: Sleep and wakefulness. In Caffeine. Coffee, and Health, ed Garattini S, New York: Raven Press, 1993: 255-290.
13. Ogunremi OO, Mamora AO. Cola acuminata (Kolanut) and coffee: acute effects on sleep of Nigerians. Psychopathologie Africaine 1980; 16: 69-75.
14. Shi J, Benowitz NL, Denaro CP, Sheiner LB. Pharmacokinetic-pharmacodynamic modelling of caffeine: tolerance to pressor effects. Clin Pharmacol Ther 1993; 53: 6-14.
15. Bertilsson L, Carrillo JA, Dahl ML, et al. Clozapine disposition covaries with the CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994; 38: 471-473.
16. Lemoine A, Gautier JC, Azoulay D, et al. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 1993; 43: 827-832.
17. Skjelbo E, Brosen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992; 34: 256-261.
18. Nielsen KK, Brøsen K, Hansen J, Gram LF. Single-dose kinetics of clomipramine: Relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 1994; 55: 518-527.
19. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P450 1A2. Biochem Pharmacol 1993; 45: 1211-1214.
20. Jerling M, Lindström L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: Evidence from a Therapeutic Drug Monitoring Service. Ther Drug Monit 1994; 16: 368-374.
21. Hiemke C, Weigmann H, Härtter S, Dahmen N, Wetzel H, Muller H. Elevated levels of clozapine in serum after addition of Fluvoxamine. J Clin Psychopharmacol 1994; 14: 279-281.
22. Vainer JL, Chouinard G. Interaction between caffeine and clozapine. J Clin Psychopharmacol 1994; 14: 284.
23. Carrillo JA, Jerling M, Bertilsson L. Comments to 'Interaction between caffeine and clozapine' J Clin Psychopharmacol 1995; 15: 376-377.
24. Baldwin HA, File SE. Caffeine-induced anxiogenesis: The role of adenosine, benzodiazepine and noradrenergic receptors. Pharmacol Biochem Behav 1989; 32: 181-186.
25. Curry ML, Curry SH, Marroum PJ. Interaction of phenothiazine and related drugs and caffeinated beverages. DICP, Annals Pharmacother 1991; 25: 437.
26. Kalow W, Tang BK. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 1991; 49: 44-48.
27. Oliveto AH, Hughes JR, Terry SY, et al. Effects of caffeine on tobacco withdrawal. Clin Pharmacol Ther 1991; 50: 157-164.
28. Haring C, Fleischhacker WW, Schett P, Humpel C, Barnas C, Saria A. Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry 1990; 147: 1471-1475.